Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
Clinical trial NCT06227117 · RECRUITING
Trial details
- NCT number
- NCT06227117
- Sponsor
- RemeGen Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-27
- Primary completion
- 2025-12-01
- Enrollment
- 120
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.